1.2100
+0.0100
+(0.83%)
As of 12:08:54 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 1 | 2 |
| Avg. Estimate | -0.01 | -0.01 | -0.04 | -0.04 |
| Low Estimate | -0.01 | -0.01 | -0.04 | -0.05 |
| High Estimate | -0.01 | -0.01 | -0.04 | -0.03 |
| Year Ago EPS | -0.01 | 0.01 | -0.04 | -0.04 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Actual | -0.01 | 0.01 | -0.01 | -0.01 |
| Difference | 0 | 0.02 | 0 | 0 |
| Surprise % | 6.67% | 230.00% | 0.00% | 20.00% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.01 | -0.01 | -0.04 | -0.04 |
| 7 Days Ago | -0.01 | -0.01 | -0.04 | -0.04 |
| 30 Days Ago | -0.01 | -0.01 | -0.04 | -0.05 |
| 60 Days Ago | -0.01 | -0.01 | -0.04 | -0.05 |
| 90 Days Ago | -0.01 | -0.01 | -0.04 | -0.05 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CMMB | 28.57% | -176.92% | 6.98% | 0.00% |
| S&P 500 | 6.76% | 5.73% | 9.19% | 14.14% |
Upgrades & Downgrades
| Maintains | Maxim Group: Buy to Buy | 2/20/2025 |
| Reiterates | Oppenheimer: Outperform to Outperform | 11/15/2024 |
| Initiated | Maxim Group: Buy | 5/13/2024 |
| Upgrade | Oppenheimer: Perform to Outperform | 5/6/2024 |
| Maintains | Oppenheimer: Perform to Perform | 3/8/2024 |
| Initiated | Roth MKM: Buy | 10/6/2023 |
Related Tickers
MDNAF Medicenna Therapeutics Corp.
0.7200
+6.51%
ATYR aTyr Pharma, Inc.
2.9900
-0.66%
MTVA MetaVia Inc.
1.1607
-36.92%
SRRK Scholar Rock Holding Corporation
30.40
+5.06%
INZY Inozyme Pharma, Inc.
0.9601
-0.93%
MIRM Mirum Pharmaceuticals, Inc.
38.93
-1.67%
PTGX Protagonist Therapeutics, Inc.
46.74
+3.79%
ALEC Alector, Inc.
1.0400
+6.04%
PBM Psyence Biomedical Ltd.
0.5088
+7.14%
PYPD PolyPid Ltd.
2.5500
-1.54%